Visit nic-s.com

About Enorama Pharma

Enorama Pharma is a Swedish innovative pharmaceutical company focused on the development and manufacturing of high-quality, consumer-friendly products within the tobacco-free white snus category. The company has filed patent applications covering proprietary formulations developed for this segment.

The products are marketed under the company’s own NIC-S® brand as well as through private label arrangements for other brands. The United States is the company’s most strategically important market. As part of its Pre-Market Tobacco Product Application (PMTA), Enorama has received an Acceptance Letter from the FDA, which has allowed sales of the company’s products while FDA-required documentation is finalized. The objective is to obtain a permanent marketing authorization — a Marketing Granted Order (MGO).

Enorama Pharma is headquartered in Stockholm, Sweden, and also has a wholly owned subsidiary in Florida, USA. The company has been listed on the Nasdaq First North Growth Market since June 10, 2016.

Vision, strategy and objectives

1.

Vision

Enorama Pharma’s vision is to help nicotine users worldwide make smarter choices and to enhance the nicotine experience through the NIC-S® brand.

2.

Strategy

The company’s strategy is to focus exclusively on tobacco-free white snus, with particular priority given to the rapidly growing U.S. market. Growth will be driven through strategic partnerships, commercialization of the NIC-S® brand, and continued development of the product portfolio.

3.

Objectives

The company aims to establish NIC-S® as a successful niche brand in relevant markets.

Interested in Becoming a Strategic Partner?

Enorama’s growth is largely driven by strategic partnerships, primarily within sales and licensing.
Contact us